Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Exclusion Criteria

• •1. Cancer therapy/ any cancer investigational drug within 3 weeks (21 days) or 5 half-lives (whichever is shorter).
• •2. Patient who has not recovered from acute toxicities of previous therapy except treatment-related alopecia.
• •3. Prior exposure to PI3K inhibitors (e.g., alpelisib, buparlisib) for breast cancer.
• •4. Major surgery within 4 weeks of starting study treatment.
• •5. Patient with symptomatic uncontrolled brain metastasis.
• •6. Ongoing immunosuppressive therapy including systemic corticosteroids.
• •7. History of severe cutaneous reactions.
• •8. Concurrent disease or condition that would interfere with study participation
• •9. Pregnancy or lactation.
• •10. Any severe and/or uncontrolled medical conditions or other conditions that could affect patient participation